Stephen T Durant (Stephen Durant)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 12

Top Topics

Dna Damage Response

Oxidative Stress

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Cancer research

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

Haojian Li, Yue Liu, Yunjie Xiao, Crystal N Wilson, Hui Jen Bai, Maxwell D Jones, Shihchun Wang, Jennie E DeVore, Esther Y Maier, Stephen T Durant, Myriem Boufraqech, Urbain Weyemi
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Haojian Li, Yue Liu, Yunjie Xiao, Crystal N Wilson, Hui Jen Bai, Maxwell D Jones, Shihchun Wang, Jennie E DeVore, Esther Y Maier, Stephen T Durant, Myriem Boufraqech, Urbain Weyemi
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Ben Yi Tew, Alex J Kalfa, Zeyi Yang, Kyle M Hurth, Thomas Simon, Eric Abnoosian, Stephen T Durant, Petra Hamerlik, Bodour Salhia
ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Haojian Li, Yue Liu, Yunjie Xiao, Crystal N Wilson, Hui Jen Bai, Maxwell D Jones, Shihchun Wang, Jennie E DeVore, Esther Y Maier, Stephen T Durant, Myriem Boufraqech, Urbain Weyemi
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Haojian Li, Yue Liu, Yunjie Xiao, Crystal N Wilson, Hui Jen Bai, Maxwell D Jones, Shihchun Wang, Jennie E DeVore, Esther Y Maier, Stephen T Durant, Myriem Boufraqech, Urbain Weyemi
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Haojian Li, Yue Liu, Yunjie Xiao, Crystal N Wilson, Hui Jen Bai, Maxwell D Jones, Shihchun Wang, Jennie E DeVore, Esther Y Maier, Stephen T Durant, Myriem Boufraqech, Urbain Weyemi
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Haojian Li, Yue Liu, Yunjie Xiao, Crystal N Wilson, Hui Jen Bai, Maxwell D Jones, Shihchun Wang, Jennie E DeVore, Esther Y Maier, Stephen T Durant, Myriem Boufraqech, Urbain Weyemi
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. Proceedings of the National Academy of Sciences of the United States of America 120 (6) (2023)
Massimiliano Mellone, Klaudia Piotrowska, Giulia Venturi, Lija James, Aleksandra Bzura, Maria A Lopez, Sonya James, Chuan Wang, Matthew J Ellis, Christopher J Hanley, Josephine F Buckingham, Kerry L Cox, Gareth Hughes, Viia Valge-Archer, Emma V King, Stephen A Beers, Vincent Jaquet, George D D Jones, Natalia Savelyeva, A Emre Sayan, Jason L Parsons, Stephen T Durant, Gareth J Thomas
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance. Cancer research (2022)
Balakrishna Koneru, Ahsan S Farooqi, Thinh Hoang Nguyen, Wan Hsi Chen, Ashly Hindle, Cody Eslinger, Monish Ram Makena, Trevor A Burrow, Joanne Wilson, Aaron Smith, Venkatesh Pilla Reddy, Elaine B Cadogan, Stephen T Durant, C Patrick Reynolds
ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156. Science translational medicine 13 (607) (2021)
Gabriel Balmus, Domenic Pilger, Julia Coates, Mukerrem Demir, Matylda Sczaniecka-Clift, Ana C Barros, Michael Woods, Beiyuan Fu, Fengtang Yang, Elisabeth D Chen, Matthias Ostermaier, Tatjana Stankovic, Hannes Ponstingl, Mareike Herzog, Kosuke Yusa, Francisco Munoz Martinez, Stephen T Durant, Yaron Galanty, Petra Beli, David J Adams, Allan Bradley, Emmanouil Metzakopian, Josep V Forment, Stephen P Jackson
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks. Nature communications 10 (1) (2019)
Stephen T Durant, Li Zheng, Yingchun Wang, Kan Chen, Lingli Zhang, Tianwei Zhang, Zhenfan Yang, Lucy Riches, Antonio G Trinidad, Jacqueline H L Fok, Thomas A Hunt, Kurt G Pike, Joanne Wilson, Aaron Smith, Nicola Colclough, Venkatesh Pilla Reddy, Andrew Sykes, Annika Janefeldt, Peter Johnström, Katarina Varnäs, Akihiro Takano, Stephanie Ling, Jonathan Orme, Jonathan Stott, Caroline Roberts, Ian Barrett, Gemma Jones, Martine Roudier, Andrew Pierce, Jasmine Allen, Jenna Kahn, Amrita Sule, Jeremy Karlin, Anna Cronin, Melissa Chapman, Kristoffer Valerie, Ruth Illingworth, Martin Pass
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Science advances 4 (6) (2018)
Thomas A Ward, Peter J McHugh, Stephen T Durant
Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes. PloS one 12 (6) (2017)